BDH Industries Ltd
Incorporated in 1935, BDH Industries Ltd manufactures therapeutic formulations covering wide range of pharmaceuticals[1]
- Market Cap ₹ 233 Cr.
- Current Price ₹ 404
- High / Low ₹ 610 / 340
- Stock P/E 20.5
- Book Value ₹ 137
- Dividend Yield 1.24 %
- ROCE 20.5 %
- ROE 14.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 27.0%
Cons
- The company has delivered a poor sales growth of 10.8% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44 | 46 | 43 | 41 | 52 | 59 | 57 | 69 | 74 | 86 | 67 | 96 | 101 | |
| Sales growth | +4% | +4% | -6% | -5% | +26% | +15% | -3% | +21% | +7% | +15% | -23% | +44% | +42% |
| 40 | 42 | 38 | 36 | 45 | 51 | 49 | 60 | 64 | 73 | 55 | 82 | 87 | |
| Operating Profit | 4 | 4 | 5 | 5 | 7 | 9 | 9 | 9 | 11 | 12 | 12 | 14 | 15 |
| OPM % | 9% | 9% | 11% | 13% | 14% | 15% | 15% | 13% | 15% | 14% | 17% | 14% | 14% |
| 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 5 | 5 | 5 | 7 | 8 | 9 | 10 | 11 | 13 | 12 | 15 | 16 |
| Tax % | 32% | 33% | 33% | 27% | 26% | 27% | 27% | 24% | 26% | 25% | 26% | 29% | |
| 3 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 10 | 9 | 11 | 11 | |
| EPS in Rs | 4.46 | 5.61 | 5.80 | 6.53 | 8.39 | 10.32 | 11.05 | 12.54 | 14.24 | 17.14 | 16.10 | 18.78 | 19.74 |
| Dividend Payout % | 39% | 37% | 36% | 36% | 34% | 25% | 28% | 29% | 28% | 26% | 28% | 27% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 28% |
| 3 Years: | 29% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 15% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 18 | 21 | 23 | 25 | 28 | 32 | 37 | 43 | 49 | 56 | 63 | 71 | 73 |
| 9 | 9 | 8 | 8 | 13 | 9 | 9 | 2 | 5 | 9 | 1 | 2 | 0 | |
| 19 | 15 | 17 | 18 | 18 | 18 | 19 | 18 | 20 | 23 | 17 | 20 | 11 | |
| Total Liabilities | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 99 | 90 |
| 13 | 13 | 23 | 23 | 22 | 21 | 20 | 20 | 19 | 20 | 20 | 19 | 19 | |
| CWIP | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 38 | 35 | 31 | 34 | 44 | 44 | 51 | 49 | 61 | 73 | 67 | 80 | 71 | |
| Total Assets | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 99 | 90 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 4 | 7 | -0 | -4 | 11 | 1 | 3 | 6 | -2 | 15 | -2 | |
| -0 | -5 | -5 | 0 | 1 | 1 | 1 | 1 | 0 | -0 | 2 | 2 | |
| -3 | -1 | -3 | -3 | 3 | -6 | -2 | -8 | 0 | 1 | -10 | -2 | |
| Net Cash Flow | 3 | -1 | -1 | -2 | 0 | 6 | -0 | -4 | 7 | -1 | 6 | -2 |
| Free Cash Flow | 6 | -0 | 1 | -1 | -4 | 11 | 1 | 4 | 6 | -4 | 15 | -2 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 198% | 146% | 186% | 21% | -24% | 153% | 35% | 64% | 82% | 11% | 153% | 8% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 64 | 67 | 63 | 89 | 68 | 96 | 76 | 82 | 121 | 78 | 120 |
| Inventory Days | 71 | 61 | 39 | 95 | 89 | 51 | 53 | 50 | 53 | 30 | 65 | 28 |
| Days Payable | 201 | 162 | 192 | 244 | 188 | 158 | 171 | 123 | 139 | 128 | 134 | 91 |
| Cash Conversion Cycle | -49 | -37 | -85 | -85 | -10 | -39 | -21 | 4 | -5 | 23 | 9 | 58 |
| Working Capital Days | -76 | -72 | -90 | -60 | -29 | -31 | 6 | 56 | 49 | 71 | 102 | 116 |
| ROCE % | 13% | 15% | 14% | 14% | 16% | 19% | 18% | 18% | 20% | 21% | 18% | 20% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Sales Share % of total sales |
|
||||||||||
| Foreign Exchange Earnings Rs lakhs |
|||||||||||
| Number of permanent employees employees |
|||||||||||
| R&D Expenditure Rs lakhs |
|||||||||||
| Top customer (IPCA) revenue share % of revenue |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Kindly find the enclosed herewith the Standalone Unaudited Financial Results for the second quarter and half year ended on 30th September 2026 of the financial …
-
Standalone Unaudited Financial Results For The Second Quarter And Half Year Ended On 30Th September 2026 Of The Financial Year 2026-27.
- Board approved Q2 and half-year standalone unaudited results for 30 September 2026.
-
Board Meeting Outcome for For Standalone Unaudited Financial Results For The Second Quarter And Half Year Ended On 30Th September 2026 Of The Financial Year 2026-27.
- Board approved Q2 and H1 FY27 unaudited standalone results on 12 November 2026.
-
Board Meeting Intimation for Considering And Approving The Standalone Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September 2026 Of The Financial Year 2026-27.
- Board meets on 12 November 2026 to approve Q2 and half-year FY27 unaudited results; trading window closed till 16 November.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Kindly find the enclosed herewith the fifth Notice of special window opened for a period of one year from 5th February 2026 to 4th February …
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
BDHIL is a full-service Contract Manufacturing Organisation for the production of Pharmaceutical, Oncological Products and associated packaging services. It is an exporter and manufacturer of therapeutic formulations covering a wide range of pharmaceuticals